Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centogene AG - |
RCV000590835 | SCV001426545 | pathogenic | Developmental and epileptic encephalopathy, 59 | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV003591755 | SCV004296036 | pathogenic | Epileptic encephalopathy | 2024-10-23 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with tryptophan, which is neutral and slightly polar, at codon 693 of the GABBR2 protein (p.Gly693Trp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with developmental and epileptic encephalopathy (PMID: 29100083, 32860008, 35414446). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 496588). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt GABBR2 protein function with a negative predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000590835 | SCV000700063 | pathogenic | Developmental and epileptic encephalopathy, 59 | 2020-11-11 | no assertion criteria provided | literature only |